Nicardipine-Releasing Brain Implant Secures EMA PRIME Designation

Promising safety, tolerability and efficacy data for the NicaPlant implant formed the basis of the BIT Pharma’s application for a place on the European Medicines Agency’s priority medicines scheme.

NicaPlant, a nicardipine-releasing brain implant that BIT Pharma is developing to treat non-traumatic subarachnoid hemorrhage in patients undergoing surgery, has become the latest product to enter the European Medicines Agency’s PRIME (priority medicines) scheme.

The investigational implant allows for the slow release in situ of nicardipine, a calcium-channel blocker that has been used in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet